Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 9/20 | 0.84 |
| ▸ | PDE4B known ✓ | Q07343 | 9/20 | 0.84 |
| ▸ | PDE4C known ✓ | Q08493 | 9/20 | 0.84 |
| ▸ | PDE4D known ✓ | Q08499 | 9/20 | 0.84 |
| ▸ | ADORA2A known ✓ | P29274 | 8/20 | 0.84 |
| ▸ | ADORA2B known ✓ | P29275 | 8/20 | 0.84 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.84 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.84 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.84 |
| ▸ | ALPL | P05186 | 1/20 | 0.84 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.84 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.81 |
| ▸ | CFTR | P13569 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL1022085 | 1.00 | CYP1A2 (0.97) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL7546366 | 1.00 | CYP1A2 (0.97) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL5037 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL1321168 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL5181434 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL393183 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL11187438 | 0.97 | CYP1A2 (0.97) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL9792548 | 0.97 | CYP1A2 (0.97) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL8719730 | 0.95 | CYP1A2 (0.94) | CYP1A2LMNAMAPTPDE4APDE4B | |
| Theophylline Anhydrous SCHEMBL28274666 | 0.94 | CYP1A2 (0.91) | CYP1A2LMNAMAPTPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069551-A1 | Patch for treating demyelinating diseases | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2026-03-12 | — | — | US | disclosed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4587027-A1 | PATCH FOR TREATING DEMYELINATING DISEASES | Johannes Gutenberg-Universität Mainz (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240207279-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2024056642-A1 | PATCH FOR TREATING DEMYELINATING DISEASES | Johannes Gutenberg-Universität Mainz (DE) | 2024-03-21 | — | — | WO | disclosed |
| US-11911389-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2024-02-27 | — | — | US | disclosed |
| CN-116236441-A | Aminophylline injection and preparation method thereof | 湖南浩森制药有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2023-04-06 | — | — | US | disclosed |
| US-10758544-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | disclosed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190231786-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2019-08-01 | — | — | US | disclosed |
| CN-109890366-A | Combination medicine for treating cardiovascular diseases and preparation and use methods thereof | 美进医药公司 | 2019-06-14 | — | — | CN | disclosed |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180325907-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | CARDIX Therapeutics, LLC | 2018-11-15 | — | — | US | disclosed |
| WO-2018208723-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2018-11-15 | — | — | WO | disclosed |
| WO-2018055211-A1 | NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2018-03-29 | — | — | WO | disclosed |
| EP-3299460-A1 | NOVEL COMPOUNDS AND METHODS FOR MODULATING UBIQUITINATION | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | PDE4A 49/4885PDE4B 60/4885PDE4C 91/4885 |
| US-20230107723-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4A 49/4885PDE4B 60/4885PDE4C 91/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4A 49/4885PDE4B 60/4885PDE4C 91/4885 |
| US-20260069551-A1 | Patch for treating demyelinating diseases | PMP22, PLP2, MYT1 | PDE4A 658/4885PDE4B 1128/4885PDE4C 1249/4885 |
| US-20190070184-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | PDE4A 49/4885PDE4B 60/4885PDE4C 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.